ArticleRheumatology (Oxford, England)2024
Differences in transcriptional changes in psoriasis and psoriatic arthritis skin with immunoglobulin gene enrichment in psoriatic arthritis.
Article in Rheumatology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 8 citations in OpenAlex.
- Predicting clinical response in psoriatic arthritis through integrative analysis of transcriptomics and proteomics.Arthritis research & therapy · 2026Trial
- Transcriptomic profiling of secukinumab-treated psoriatic arthritis reveals potential novel response-associated pathways.Rheumatology (Oxford, England) · 2026Observational
- Disease context dictates the cellular targets of IL-17 in inflammatory skin disease.bioRxiv : the preprint server for biology · 2026Article
- A Novel Chronic Psoriasis Mouse Model via Optimized Imiquimod Dosing and Machine Learning Evaluation.Journal of inflammation research · 2026Article
- mRNAome Analysis of Whole Blood of Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Rheumatoid Arthritis.Current rheumatology reviews · 2026Review
- PBMC transcriptomic signatures reflect immune dynamics and disease activity in psoriatic arthritis.Frontiers in immunology · 2026Article
- Co-occurrence of endometriosis with psoriasis and psoriatic arthritis: Genetic insights (Review).Experimental and therapeutic medicine · 2025Review
- Development of a Mouse Model of Enthesis-Specific NF-κB Activation.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2025Article
- Differences between psoriatic arthritis and psoriasis in multi-omics.Archives of dermatological research · 2024Review
- Single-cell RNA sequencing highlights the influence of innate and adaptive immune response mechanisms in psoriatic arthritis.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectivesApproximately 20% of people with psoriasis develop PsA. Although genetic, clinical and environmental risk factors have been identified, it is not known why some people with psoriasis develop PsA. The skin disease is traditionally considered the same in both. This study compares transcriptional changes in psoriasis and PsA skin for the first time.
methodsSkin biopsies were collected from healthy controls (HC), and uninvolved and lesional skin from patients with PsA. Bulk tissue sequencing was performed and analysed using the pipeline Searchlight 2.0. Transcriptional changes in PsA skin were compared with existing sequencing data from participants with psoriasis without PsA (GSE121212). Psoriasis and PsA datasets could not be directly compared as different analysis methods were used. Data from participants with PsA in the GSE121212 dataset were used for validation.
resultsSkin samples from 9 participants with PsA and 9 HC were sequenced, analysed and compared with available transcriptomic data for 16 participants with psoriasis compared with 16 HC. Uninvolved skin in psoriasis shared transcriptional changes with lesional skin in psoriasis, but uninvolved skin in PsA did not. Most transcriptional changes in psoriasis and PsA lesional skin were shared, but immunoglobulin genes were upregulated in PsA lesional skin specifically. The transcription factor POU2F1, which regulates immunoglobulin gene expression, was enriched in PsA lesional skin. This was confirmed in the validation cohort.
conclusionsImmunoglobulin genes are upregulated in PsA but not in psoriasis skin lesions. This may have implications for the spread from the cutaneous compartment to other tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.